Viking Therapeutics (VKTX) Leases (2019 - 2025)
Viking Therapeutics (VKTX) has disclosed Leases for 7 consecutive years, with $85000.0 as the latest value for Q4 2025.
- Quarterly Leases fell 91.53% to $85000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $85000.0 through Dec 2025, down 91.53% year-over-year, with the annual reading at $85000.0 for FY2025, 91.53% down from the prior year.
- Leases hit $85000.0 in Q4 2025 for Viking Therapeutics, down from $666000.0 in the prior quarter.
- In the past five years, Leases ranged from a high of $1.6 million in Q1 2022 to a low of $25000.0 in Q4 2021.
- Historically, Leases has averaged $908150.0 across 5 years, with a median of $1.0 million in 2024.
- Biggest five-year swings in Leases: plummeted 92.21% in 2021 and later soared 5572.0% in 2022.
- Year by year, Leases stood at $25000.0 in 2021, then skyrocketed by 5572.0% to $1.4 million in 2022, then decreased by 20.59% to $1.1 million in 2023, then decreased by 10.92% to $1.0 million in 2024, then tumbled by 91.53% to $85000.0 in 2025.
- Business Quant data shows Leases for VKTX at $85000.0 in Q4 2025, $666000.0 in Q3 2025, and $780000.0 in Q2 2025.